CLDX Key Statistics, Chart & Performance
The current stock price of CLDX is 26.32 USD. In the past month the price decreased by -3.84%. In the past year, price decreased by -4.08%.
CLDX Latest News, Press Relases and Analysis
CLDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About CLDX
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 186 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Company Info
CELLDEX THERAPEUTICS INC
53 Frontage Road, Suite 220
Hampton NEW JERSEY 08827 US
CEO: Anthony S. Marucci
Employees: 186
Phone: 19084547120
CELLDEX THERAPEUTICS INC / CLDX FAQ
Can you describe the business of CELLDEX THERAPEUTICS INC?
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 186 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
What is the current price of CLDX stock?
The current stock price of CLDX is 26.32 USD. The price increased by 1.54% in the last trading session.
Does CLDX stock pay dividends?
CLDX does not pay a dividend.
What is the ChartMill rating of CELLDEX THERAPEUTICS INC stock?
CLDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the ownership structure of CELLDEX THERAPEUTICS INC (CLDX)?
You can find the ownership structure of CELLDEX THERAPEUTICS INC (CLDX) on the Ownership tab.
Can you provide the short interest for CLDX stock?
The outstanding short interest for CELLDEX THERAPEUTICS INC (CLDX) is 11.34% of its float.
CLDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CLDX. When comparing the yearly performance of all stocks, CLDX is one of the better performing stocks in the market, outperforming 73.91% of all stocks.
CLDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CLDX. While CLDX has a great health rating, there are worries on its profitability.
CLDX Financial Highlights
Over the last trailing twelve months CLDX reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -31.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.63% | ||
| ROE | -37.52% | ||
| Debt/Equity | 0 |
CLDX Forecast & Estimates
22 analysts have analysed CLDX and the average price target is 54.21 USD. This implies a price increase of 105.95% is expected in the next year compared to the current price of 26.32.
For the next year, analysts expect an EPS growth of -45.05% and a revenue growth -47.04% for CLDX